NWNancy Wang

Nancy Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nancy Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian Hunt

    University of Sydney, Sydney Medical School, Discipline of Ophthalmology and Eye Health Save Sight Institute New South Wales Australia

    1 shared publication
  • Chris Murphy

    Department of Ophthalmology, Waikato District Health Board, Hamilton, New Zealand

    1 shared publication
  • Corina M. Chilibeck

    Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand

    1 shared publication
  • Daniel Barthelmes

    Department of Ophthalmology University Hospital of Zurich Zurich Switzerland

    1 shared publication
  • David Squirrell

    Department of Ophthalmology University of Auckland Auckland New Zealand

    1 shared publication
  • Ian McAllister

    Lions Eye Institute University of Western Australia Nedlands Australia

    1 shared publication

Latest Publications

  • One‐year real‐world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion

    by Nancy Wang, Adrian Hunt, Vuong Nguyen, Janika Shah, Samantha Fraser‐Bell, Ian McAllister, Daniel Barthelmes, Mark Gillies, David Squirrell

    Background: Bevacizumab is the only agent that many people can afford, yet there are only limited data on whether it improves macular oedema (MO) secondary to retinal vein occlusion (RVO) in real‐world clinical practice. Here we studied 12‐month real‐world treatment outcomes of bevacizumab for RVO‐related MO.Methods: This was a multicentre, observational study analysing 12‐month data from the Fight Retinal Blindness! (FRB) database. We studied treatment‐naïve eyes with MO secondary to RVO commencing bevacizumab therapy between June 2009 and June 2019. Visual acuity (VA) and central subfield thickness (CST) were measured at baseline, 6 and 12 months. The primary outcome was a change in VA from baseline to 12 months.Results: Two hundred and twenty treatment naive eyes were analyzed. The baseline VA for BRVO was better than CRVO (55.8 vs. 42.6 LogMAR letters) and this gap widened over the 12‐month period, with a 12‐month VA change of +14.0 (95% CI 11.1, 16.8) letters for BRVO and + 11.9 (95% CI 6.4, 17.4) for CRVO. The mean CST at baseline was 511 μm for BRVO and 627 μm for CRVO, falling at 12 months by −155 μm (−190, −121) in BRVO and −198 μm (−252, −145) in CRVO. The median number of injections for BRVO and CRVO completers was 7 (5, 9).Conclusions: Bevacizumab can be an effective treatment of RVO‐MO in a real‐world setting with outcomes approaching those reported by the seminal clinical trials. The functional and anatomical outcomes of intravitreal therapy were better for BRVO than CRVO.


  • Better visual outcome associated with early vitrectomy in the management of endophthalmitis

    by Sarah Welch, Riyaz Bhikoo, Nancy Wang, Martin J Siemerink, William Shew, Philip J Polkinghorne, Rachael L Niederer

    Aims To examine the role of early vitrectomy in the management of endophthalmitis from all causes. Methods Retrospective study of 290 consecutive subjects diagnosed with endophthalmitis at Auckland District Health Board between 1 January 2006 and 31 July 2019. Main outcome measure was visual acuity at 9-month follow-up and proportion of subjects with severe vision loss (≤20/200). Results Median age at presentation was 70.4 years and 151 subjects (52.1%) were women. Cataract surgery was the most common cause of endophthalmitis in 92 subjects (31.7%) followed by intravitreal injection in 57 (19.7%), endogenous endophthalmitis in 48 subjects (16.6%), non-surgical trauma in 42 subjects (14.5%), glaucoma surgery in 24 subjects (8.3%), vitrectomy in 22 subjects (7.6%) and corneal in 5 subjects (1.7%). Culture was positive in 136 (46.9%) with gram-positive organisms most common (76.5%). Early vitrectomy was performed in 82 subjects (28.3%). Median visual acuity at 9 months was 20/100 (IQR 20/30 to light perception), and severe vision loss occurred in 100 (43.5%). Retinal detachment occurred in 35 eyes (12.1%) and 26 eyes were enucleated. On multivariate analysis, younger age, poor presenting visual acuity and culture-positive endophthalmitis were associated with worse outcomes, and early vitrectomy was associated with better outcomes. Conclusions Early vitrectomy (within 24 hours) is associated with better visual outcomes at 9 months, while younger age, poor presenting visual acuity and culture-positive endophthalmitis are associated with poorer visual acuity outcomes.


  • Making a bee-line for the eye: a limbal sting and retained honey bee

    by Corina Chilibeck, Nancy Wang, Chris Murphy

    A 28-year-old Caucasian male presented with pain, redness, foreign body sensation, reduced vision, and lid swelling after a honey bee collided with his left eye whilst driving an all-terrain vehicl...


  • Open Access

    Coincident keratoconus and Fuchs' endothelial dystrophy: Dual dystrophies mask progression

    by Nancy Wang, James McKelvie

    We present an interesting case of a 58-year-old woman who presented coincident keratoconus and Fuchs' endothelial dystrophy. During the 7months following initial presentation, a decline in visual acuity was associated with an apparent improvement in keratoconus, as characterized by corneal tomography parameters, while an increase in corneal pachymetry was also observed. The patient has been managed with left endothelial keratoplasty. This case poses the interesting question of how to classify coincident corneal disease, as traditional parameters for grading the severity of KC are altered by the presence of Fuchs' Endothelial Corneal Dystrophy and vice versa. In such cases, it is important to be aware of coincident disease to more accurately assess progression when considering treatment options and timing.